SF3B1 and malignant endocrine neoplasm: Future efforts of employing oligonucleotide therapy (such as antisense oligonucleotides, ASO and splice switching oligonucleotides, SSO), targeting critical splicing modulator (such as SF3B1, a core component in spliceosome), or screening/developing compounds specifically inhibiting PI3Kδ-S activity, may further warrant the development of novel therapies for overcoming the Idelalisib resistance in the PI3Kδ-expressing endocrine cancers.